<bill session="116" type="h" number="7917" updated="2023-01-11T13:45:45Z">
  <state datetime="2020-07-31">REFERRED</state>
  <status>
    <introduced datetime="2020-07-31"/>
  </status>
  <introduced datetime="2020-07-31"/>
  <titles>
    <title type="display">IGNITE American Innovation Act</title>
    <title type="short" as="introduced">IGNITE American Innovation Act</title>
    <title type="short" as="introduced">Innovation and Growth Now by Investing in Tomorrow&#226;&#8364;&#8482;s Enterprises Act</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to provide for advance refunds of certain net operating losses and research expenditures relating to COVID-19, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="P000616"/>
  <cosponsors>
    <cosponsor bioguide_id="B001275" joined="2020-10-20"/>
    <cosponsor bioguide_id="C001114" joined="2020-08-14"/>
    <cosponsor bioguide_id="S001192" joined="2020-09-29"/>
    <cosponsor bioguide_id="W000813" joined="2020-07-31"/>
  </cosponsors>
  <actions>
    <action datetime="2020-07-31">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-07-31" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
    <action datetime="2020-07-31">
      <text>Referred to the Subcommittee on Select Revenue Measures.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSWM05" name="House Ways and Means" subcommittee="Tax" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Appropriations"/>
    <term name="Business expenses"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Corporate finance and management"/>
    <term name="Disability assistance"/>
    <term name="Drug therapy"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Government trust funds"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Income tax credits"/>
    <term name="Income tax deductions"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Medical research"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
    <term name="Research and development"/>
    <term name="Social security and elderly assistance"/>
  </subjects>
  <amendments/>
  <summary date="2021-05-25T14:36:44Z" status="Introduced in House">Innovation and Growth Now by Investing in Tomorrow's Enterprises Act or the IGNITE American Innovation Act

This bill allows certain C corporation taxpayers to elect an increased advance refund of net operating loss carryovers attributable to COVID-19 (i.e., coronavirus disease 2019) research expenditures in 2020 and 2021. The bill also allows such taxpayers an advance refund of certain other net operating loss carryovers arising during 2015 through 2021.

The bill allows an increased research tax credit for COVID-19 research expenditures paid or incurred on or after February 15, 2020, and before January 1, 2022.</summary>
</bill>
